As of mid-2026, neither cagrilintide nor retatrutide is FDA- or EMA-approved for any indication, and no legitimate prescription product exists for either
Both peptides are referenced in scientific literature for their involvement in cellular signaling, structural protein interaction, and coordinated tissue response pathways in preclinical research
Compounded semaglutide faces evolving FDA regulations
Retatrutide demonstrates significant liver health improvements in clinical research
By combining genetic context with clinical assessment, individuals can have more informed conversations with their provider about whether compounded semaglutide or tirzepatide better aligns with their metabolic profile
It offers semaglutide and tirzepatide as compounded formulations through its Weight Management Protocols, including Semaglutide Injection and Semaglutide Oral, with published per-protocol pricing